Literature DB >> 18651214

Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm.

Xiaoming Yang1, Patricia A Wood, Eun-Young Oh, Jovelyn Du-Quiton, Christine M Ansell, William J M Hrushesky.   

Abstract

Purpose Per2, a core circadian clock gene, has tumor suppressor properties and is mutated or down regulated in human breast cancers. We have manipulated the expression of this gene in vitro and in vivo to more fully understand how the Per2 clock gene product affects cancer growth. Methods We used siRNA and shRNA to down regulate Per2 expression in vitro and in vivo and measured cancer cell proliferation, tumor growth rate and several molecular pathways relevant to cancer growth and their circadian organizations. All statistical tests were two-sided. Results Down regulation of functional Per2 gene expression increases Cyclin D and Cyclin E levels and doubles in vitro breast cancer cell proliferation (P < 0.05). Down regulation of Per2 also accelerates in vivo tumor growth and doubles the daily amplitude of the tumor growth rhythm (P < 0.05). Conclusions The clock gene Per2 exerts its tumor suppressor function in a circadian time dependent manner. Therefore, Per2 and perhaps other clock genes represent a new class of potential therapeutic targets whose manipulation will modulate cancer growth and cancer cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18651214     DOI: 10.1007/s10549-008-0133-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  58 in total

Review 1.  Circadian rhythms and cancer.

Authors:  Sigal Gery; H Philip Koeffler
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

2.  The role of circadian rhythm in breast cancer.

Authors:  Shujing Li; Xiang Ao; Huijian Wu
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

Review 3.  Circadian rhythm disruption in cancer biology.

Authors:  Christos Savvidis; Michael Koutsilieris
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

4.  Drug release kinetics, cell uptake, and tumor toxicity of hybrid VVVVVVKK peptide-assembled polylactide nanoparticles.

Authors:  Esmaiel Jabbari; Xiaoming Yang; Seyedsina Moeinzadeh; Xuezhong He
Journal:  Eur J Pharm Biopharm       Date:  2012-12-27       Impact factor: 5.571

5.  Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells.

Authors:  Yongjun Wang; Douglas Kojetin; Thomas P Burris
Journal:  Biochem Pharmacol       Date:  2015-06-12       Impact factor: 5.858

6.  Circadian gene expression and clinicopathologic correlates in pancreatic cancer.

Authors:  Daniel Relles; Jocelyn Sendecki; Galina Chipitsyna; Terry Hyslop; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2012-12-20       Impact factor: 3.452

7.  Chronotype and breast cancer risk in a cohort of US nurses.

Authors:  Cody Ramin; Elizabeth E Devore; Jeffrey Pierre-Paul; Jeanne F Duffy; Susan E Hankinson; Eva S Schernhammer
Journal:  Chronobiol Int       Date:  2013-08-20       Impact factor: 2.877

8.  Period 1 and estrogen receptor-beta are downregulated in Chinese colon cancers.

Authors:  Yupeng Wang; Tonghai Xing; Li Huang; Guohe Song; Xing Sun; Lin Zhong; Junwei Fan; Dongwang Yan; Chongzhi Zhou; Feifei Cui; Fudong Yu; Jian Chen; Yang Yu; Chao Li; Huamei Tang; Zhihai Peng; Xiaoliang Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  Expression of cell cycle regulatory factors hus1, gadd45a, rb1, cdkn2a and mre11a correlates with expression of clock gene per2 in human colorectal carcinoma tissue.

Authors:  Mária Štorcelová; Marián Vicián; Richard Reis; Michal Zeman; Iveta Herichová
Journal:  Mol Biol Rep       Date:  2013-09-24       Impact factor: 2.316

10.  The effect of melatonin on sleep and quality of life in patients with advanced breast cancer.

Authors:  Pasquale F Innominato; Andrew S Lim; Oxana Palesh; Mark Clemons; Maureen Trudeau; Andrea Eisen; Cathy Wang; Alex Kiss; Kathleen I Pritchard; Georg A Bjarnason
Journal:  Support Care Cancer       Date:  2015-08-11       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.